# Xilio Development, Inc.: Phase 2 study started recruiting, 180 planned (Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Xilio Development, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors |
| NCT ID | NCT07688577 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor |
| Intervention types | drug |
| Target enrollment | 180 |
| Site countries | United States |
| Posted | 2026-07-07 |
| Planned start | 2026-10-21 |
| Event | Started recruiting |
| Event date | 2026-10-21 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 180 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07688577). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.